Participant flow

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma · Source last updated 2024-12-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin Pemetrexed

   id

   FG000

   title

   Arm A - Cisplatin/Pemetrexed (Phase II)

2. description

   Pembrolizumab 200 mg\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin Pemetrexed Pembrolizumab

   id

   FG001

   title

   Arm B - Cisplatin/Pemetrexed/Pembrolizumab (Phase II)

3. description

   Pembrolizumab 200 mg\* IV 30 min Day 1 every 21 days for a total of 2 years Pembrolizumab

   id

   FG002

   title

   Arm C - Pembrolizumab (Phase II Only)

4. description

   Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin Pemetrexed

   id

   FG003

   title

   Arm A - Cisplatin/Pemetrexed (Phase III)

5. description

   Pembrolizumab 200 mg\* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin Pemetrexed Pembrolizumab

   id

   FG004

   title

   Arm B - Cisplatin/Pemetrexed/Pembrolizumab (Phase III)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         21

      2. group Id

         FG001

         num Subjects

         19

      3. group Id

         FG002

         num Subjects

         40

      4. group Id

         FG003

         num Subjects

         218

      5. group Id

         FG004

         num Subjects

         222

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         21

      2. group Id

         FG001

         num Subjects

         19

      3. group Id

         FG002

         num Subjects

         40

      4. group Id

         FG003

         num Subjects

         218

      5. group Id

         FG004

         num Subjects

         222

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice